AVT05 (golimumab biosimilar) / Alvotech, Lupin, Teva 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
AVT05 (golimumab biosimilar) / Alvotech, Lupin, Teva
2022-001825-63: A Clinical Study to Investigate the Comparative Efficacy, Safety, and Immunogenicity Between Subcutaneous AVT05 and EU-approved Simponi® in Combination with Methotrexate in Subjects with Moderate to Severe Rheumatoid Arthritis

Not yet recruiting
3
472
Europe, RoW
golimumab, Simponi, AVT05, Solution for injection in pre-filled syringe, Simponi
Alvotech Swiss AG, Alvotech Swiss AG
Rheumatoid Arthritis reumatoidiniu artritu, Rheumatoid Arthritis reumatoidiniu artritu, Diseases [C] - Immune System Diseases [C20]
 
 
ALVOFLEX, NCT05842213 / 2022-001825-63: Comparative, Multicenter Study in Subjects with Rheumatoid Arthritis,

Completed
3
502
Europe
AVT05 (proposed biosimilar to golimumab), Simponi (Golimumab)
Alvotech Swiss AG, Alvotech Swiss AG
Rheumatoid Arthritis
03/24
09/24
NCT05632211: A Study to Investigate the PK, Safety, and Tolerability Between AVT05, US and EU Simponi® in Healthy Adult Participants

Completed
1
336
Europe, RoW
AVT05, Simponi, Golimumab
Alvotech Swiss AG, Iqvia Pty Ltd
Healthy Adult Subjects
10/23
10/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
AVT05 (golimumab biosimilar) / Alvotech, Lupin, Teva
2022-001825-63: A Clinical Study to Investigate the Comparative Efficacy, Safety, and Immunogenicity Between Subcutaneous AVT05 and EU-approved Simponi® in Combination with Methotrexate in Subjects with Moderate to Severe Rheumatoid Arthritis

Not yet recruiting
3
472
Europe, RoW
golimumab, Simponi, AVT05, Solution for injection in pre-filled syringe, Simponi
Alvotech Swiss AG, Alvotech Swiss AG
Rheumatoid Arthritis reumatoidiniu artritu, Rheumatoid Arthritis reumatoidiniu artritu, Diseases [C] - Immune System Diseases [C20]
 
 
ALVOFLEX, NCT05842213 / 2022-001825-63: Comparative, Multicenter Study in Subjects with Rheumatoid Arthritis,

Completed
3
502
Europe
AVT05 (proposed biosimilar to golimumab), Simponi (Golimumab)
Alvotech Swiss AG, Alvotech Swiss AG
Rheumatoid Arthritis
03/24
09/24
NCT05632211: A Study to Investigate the PK, Safety, and Tolerability Between AVT05, US and EU Simponi® in Healthy Adult Participants

Completed
1
336
Europe, RoW
AVT05, Simponi, Golimumab
Alvotech Swiss AG, Iqvia Pty Ltd
Healthy Adult Subjects
10/23
10/23

Download Options